Trial Profile

A retrospective, cohort, observational study to estimate and compare costs associated with allcause health-care resource use (HCRU), SE and major bleedings between patients with NVAF initiating apixaban and patients initiating other OAC, VKAs, rivaroxaban, dabigatran

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists (Primary)
Indications Embolism; Stroke
Focus Therapeutic Use

11 Jan 2022 New trial record
03 Dec 2021 Results presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com